- Home
- INAB vs AIFA Comparison
INAB vs AIFA Comparison
Compare INAB & AIFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INAB | AIFA |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 14.7M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | INAB | AIFA |
|---|---|---|
| Price | $1.10 | $2.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 71.6K | ★ 389.0K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,655,039.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.50 |
| 52 Week Low | $0.88 | $1.52 |
| 52 Week High | $2.73 | $3.45 |
Technical Indicators
Market Signals| Indicator | INAB | AIFA |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 70.36 |
| Support Level | N/A | $1.62 |
| Resistance Level | $1.50 | $3.45 |
| Average True Range (ATR) | 0.10 | 0.34 |
| MACD | 0.02 | 0.17 |
| Stochastic Oscillator | 70.36 | 79.97 |
Price Performance
Historical ComparisonAbout INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.